Pediatric Dermatomyositis

Educational clinical summary of Pediatric Dermatomyositis for doctors and students: definition, workup, management, and key caveats. Not a substitute for guidelines.

Maintained by Dr. Vivek Karn Review process: editorial policy

Disclaimer: This information is for educational purposes for healthcare professionals and is not a substitute for clinical judgment. Treatment should be managed by a pediatric rheumatologist.

Overview

Definition: Juvenile Dermatomyositis (JDM) is a rare, multisystemic autoimmune inflammatory microangiopathy characterized by proximal muscle weakness and pathognomonic skin rashes. It is the most common pediatric inflammatory myopathy.
Epidemiology:
- Incidence: 2–4 per million children per year.
- Demographics: Median age of onset is 7 years; females are affected more frequently than males (2:1 to 5:1 ratio).
Classification: Classified under the 2017 EULAR/ACR Classification Criteria for Adult and Juvenile Idiopathic Inflammatory Myopathies (IIM). Unlike the adult form, JDM is rarely associated with malignancy.

Pathophysiology

Mechanism: Humoral-mediated autoimmune attack (Type I interferon signature) directed against the muscle microvasculature. This leads to complement-mediated (C5b-9) endothelial damage, capillary loss, muscle ischemia, and subsequent myofiber atrophy.
Risk Factors:
- Genetic: HLA-DRB10301, HLA-B08, and TNF-α -308A polymorphism.
- Environmental: Preceding infections (e.g., Coxsackie B), UV light exposure (often triggers rash onset).
Protective Factors: None definitively identified, though photoprotection may prevent flares.

Clinical Presentation

Signs and Symptoms

Cardinal Features: Symmetric proximal muscle weakness (girdle muscles) and characteristic skin rashes.
Early Signs: Low-grade fever, malaise, anorexia, irritability, "clumsiness," or difficulty climbing stairs.
Advanced Signs: Calcinosis cutis (20-40% of cases), dysphagia, dysphonia, and significant muscle atrophy.
Atypical Presentations: Clinically Amyopathic JDM (skin disease without clinical weakness for >6 months).

Physical Examination

Inspection:
- Gottron Papules: Erythematous to violaceous papules over the dorsal aspect of MCP, PIP, and DIP joints.
- Heliotrope Rash: Violaceous discoloration of the upper eyelids, often with periorbital edema.
- Shawl/V-sign: Photosensitive malar or chest rashes.
- Nailfold Capillaroscopy: Dilated capillary loops, drop-out, and hemorrhages (marker of systemic vasculopathy).
Palpation: Muscle tenderness (rare), subcutaneous calcifications (firm, "stony" nodules).
Special Tests:
- Childhood Myositis Assessment Scale (CMAS): Standardized tool to assess muscle strength/endurance.
- Manual Muscle Testing (MMT-8): Evaluation of 8 specific muscle groups.

Diagnostic Approach

History Taking

Key Questions: "Does your child have trouble getting off the floor (Gowers' sign)?" "Is there a change in voice or swallowing?" "Does the rash get worse after sun exposure?"
Red Flags: Dysphagia, respiratory distress (suggests ILD or respiratory muscle weakness), "woody" induration of muscles.

Laboratory Tests

First-Line:
- Muscle enzymes: CPK, Aldolase, LDH, ALT, AST (Note: Enzymes can be normal in 10-15%).
- Inflammatory markers: ESR/CRP (often surprisingly normal).
Confirmatory:
- Myositis-Specific Antibodies (MSAs): Anti-p154/155 (TIF1-γ) – most common in JDM; Anti-NXP2 (associated with calcinosis); Anti-MDA5 (associated with severe skin disease and ILD).
Monitoring: Frequent CPK and Aldolase monitoring; Von Willebrand Factor antigen (marker of endothelial damage).

Imaging

Recommended: MRI of Large Muscles (Thighs): STIR sequences are highly sensitive for detecting muscle edema and identifying optimal biopsy sites.
Advanced: Chest CT (if ILD suspected); Barium swallow (for dysphagia).

Management

Acute Management

Immediate: Assess airway and swallowing (risk of aspiration).
Stabilization: High-dose corticosteroids to halt the systemic microangiopathy.
Emergency: Intravenous Methylprednisolone (IVMP) 30 mg/kg/dose (max 1g) for 3 consecutive days for severe weakness or vasculitis.

Chronic Management

Pharmacological:
- Corticosteroids: Prednisone 2 mg/kg/day (tapered slowly over 12-24 months).
- Methotrexate (MTX): Standard of care. 15 mg/m² (max 25mg) once weekly (SQ preferred).
- IVIG: 2 g/kg monthly for refractory skin or muscle disease.
- Hydroxychloroquine: Useful for skin-predominant disease.
Non-pharmacological:
- Photoprotection: High-SPF sunscreen and UV-protective clothing are mandatory.
- Physical Therapy: Early ROM to prevent contractures; progressive resistance training once inflammation correlates subside.

Treatment Algorithms

First-Line: Oral Prednisone + Weekly Methotrexate.
Second-Line: Add IVIG or Mycophenolate Mofetil (MMF).
Refractory Cases: Rituximab, Cyclophosphamide (for ILD/severe vasculitis), or JAK inhibitors (Tofacitinib/Baricitinib - emerging evidence).

Complications

Common: Lipodystrophy (loss of subcutaneous fat), insulin resistance.
Serious: Macrophage Activation Syndrome (MAS), Interstitial Lung Disease (ILD), GI perforation (due to vasculitis).
Long-term: Calcinosis cutis, stunted growth (steroid-induced), permanent muscle atrophy.

Prognosis

Factors: Delay in treatment (>4 months) is the strongest predictor of poor outcome. Chronic-active disease course carries higher risk.
Survival: 95% 10-year survival rate in modern cohorts.
Quality of Life: Most children achieve remission, but 40-50% may follow a chronic polycyclic or continuous course necessitating long-term therapy.

Prevention

Primary: No known prevention.
Secondary: Early diagnosis and aggressive initial treatment to prevent the "burn-out" phase of permanent muscle damage.
Tertiary: Strict UV protection and Vitamin D/Calcium supplementation (to prevent osteoporosis from steroids).

Special Populations

Pediatric: Specific focus on growth monitoring and school re-integration.
Pregnancy/Geriatric: Not typically applicable given the "Juvenile" designation (onset <18 years).

Clinical Pearls

Diagnostic: A normal CPK does not rule out JDM; check Aldolase.
Treatment: Never taper steroids rapidly; JDM is prone to "rebound" flares.
Pitfalls: Don't overlook nailfold capillaries; they are often the most sensitive indicator of disease activity when labs are confusing.

Recent Updates

Guidelines: The CARRA (Childhood Arthritis and Rheumatology Research Alliance) Consensus Treatment Plans emphasize the early use of Methotrexate alongside steroids.
Evidence: Recent trials underscore the efficacy of Abatacept and JAK inhibitors in refractory JDM.
Controversies: The role of muscle biopsy is declining in favor of high-quality MRI, though it remains the gold standard for diagnostic uncertainty.

Key References

Guidelines: Lundberg IE, et al. 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies. Ann Rheum Dis.
Studies: Huber AM, et al. (2017). Medium- versus High-dose Corticosteroids in Juvenile Dermatomyositis. Arthritis & Rheumatology.
Reviews: Kim S, et al. (2020). Juvenile Dermatomyositis: State of the Art. Pediatrics.